KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Raw Materials: 2011-2012

Historic Raw Materials for Vertex Pharmaceuticals (VRTX) over the last 2 years, with Sep 2012 value amounting to $4.5 million.

  • Vertex Pharmaceuticals' Raw Materials fell 77.58% to $4.5 million in Q3 2012 from the same period last year, while for Sep 2012 it was $4.5 million, marking a year-over-year decrease of 77.58%. This contributed to the annual value of $32.2 million for FY2011, which is N/A change from last year.
  • According to the latest figures from Q3 2012, Vertex Pharmaceuticals' Raw Materials is $4.5 million, which was down 11.21% from $5.1 million recorded in Q2 2012.
  • Over the past 5 years, Vertex Pharmaceuticals' Raw Materials peaked at $32.2 million during Q4 2011, and registered a low of $4.5 million during Q3 2012.
  • Its 2-year average for Raw Materials is $16.4 million, with a median of $14.0 million in 2011.
  • Examining YoY changes over the last 5 years, Vertex Pharmaceuticals' Raw Materials showed a top increase of 264.76% in 2012 and a maximum decrease of 77.58% in 2012.
  • Over the past 2 years, Vertex Pharmaceuticals' Raw Materials (Quarterly) stood at $32.2 million in 2011, then slumped by 77.58% to $4.5 million in 2012.
  • Its Raw Materials stands at $4.5 million for Q3 2012, versus $5.1 million for Q2 2012 and $28.5 million for Q1 2012.